Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial

Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial

<p>Background: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) ch...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Landray, M, Haynes, R, Hopewell, J, Parish, S, Aung, T, Tomson, J, Wallendszus, K, Craig, M, Jiang, L, Collins, R
Formaat:	Journal article
Gepubliceerd in:	Massachusetts Medical Society 2014

Gelijkaardige items

Effects of extended-release niacin with laropiprant in high-risk patients.
door: Landray, M, et al.
Gepubliceerd in: (2014)

Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
door: Haynes, R, et al.
Gepubliceerd in: (2019)

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
door: HPS2-THRIVE Collaborative Group, et al.
Gepubliceerd in: (2013)

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
door: Kent, S, et al.
Gepubliceerd in: (2016)

Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study
door: Parish, S, et al.
Gepubliceerd in: (2018)

Niacin for reduction of cardiovascular risk.
door: Landray, M, et al.
Gepubliceerd in: (2014)

Niacin for reduction of cardiovascular risk.
door: Landray, M, et al.
Gepubliceerd in: (2014)

The safety, tolerability and biochemical efficacy of extended release niacin and laropiprant in a major randomised clinical trial
door: Haynes, R
Gepubliceerd in: (2013)

Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE
door: Hopewell, J, et al.
Gepubliceerd in: (2012)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
door: Helen Vosper
Gepubliceerd in: (2011-09-01)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
door: Helen Vosper
Gepubliceerd in: (2011-01-01)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
door: Ayman A Hussein, et al.
Gepubliceerd in: (2010-04-01)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
door: Klaus G Parhofer
Gepubliceerd in: (2009-11-01)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
door: Bulbulia, R, et al.
Gepubliceerd in: (2007)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed&nbsp; dyslipidemias and primary hypercholesterolemia
door: Adie Viljoen, et al.
Gepubliceerd in: (2010-05-01)

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
door: Bays HE, et al.
Gepubliceerd in: (2015-02-01)

25673 Training the Workforce During a Pandemic: Virtual Internships for Trainees
door: Lauren Aleksunes, et al.
Gepubliceerd in: (2021-03-01)

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
door: Farnier M, et al.
Gepubliceerd in: (2014-05-01)

Commentary: Controversies in NICE guidance on chronic kidney disease.
door: Landray, M, et al.
Gepubliceerd in: (2008)

Commentary: Controversies in NICE guidance on chronic kidney disease
door: Landray, M, et al.
Gepubliceerd in: (2008)

Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials.
door: Baigent, C, et al.
Gepubliceerd in: (2004)

Niacin: old habits die hard
door: Haynes, R, et al.
Gepubliceerd in: (2016)

Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study
door: Anastazia Kei, et al.
Gepubliceerd in: (2011-01-01)

Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
door: Harper, C, et al.
Gepubliceerd in: (2023)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
door: Harper, C, et al.
Gepubliceerd in: (2021)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
door: Mihaylova, B, et al.
Gepubliceerd in: (2019)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
door: Harper, C, et al.
Gepubliceerd in: (2021)

Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.
door: Sonia Philipose, et al.
Gepubliceerd in: (2012-01-01)

Hermansky-Pudlak Syndrome: Identification of Novel Variants in the Genes HPS3, HPS5, and DTNBP1 (HPS-7)
door: Doris Boeckelmann, et al.
Gepubliceerd in: (2022-01-01)

Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes.
door: Haynes, R, et al.
Gepubliceerd in: (2009)

Lipids in chronic kidney disease.
door: Lewis, D, et al.
Gepubliceerd in: (2010)

The HPS experiment at JLab
door: De Napoli Marzio
Gepubliceerd in: (2017-01-01)

Molecular gas in high-mass filament WB673
door: Kirsanova Maria S., et al.
Gepubliceerd in: (2017-12-01)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
door: Hopewell, J, et al.
Gepubliceerd in: (2011)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
door: Landray, M, et al.
Gepubliceerd in: (2017)

Accelerating clinical trials: time to turn words into action
door: Landray, MJ, et al.
Gepubliceerd in: (2023)

Facts about Niacin
door: R. Elaine Turner
Gepubliceerd in: (2006-08-01)

Facts about Niacin
door: R. Elaine Turner
Gepubliceerd in: (2006-08-01)

Facts about Niacin
door: R. Elaine Turner
Gepubliceerd in: (2006-08-01)

Facts About Niacin
door: R. Elaine Turner, et al.
Gepubliceerd in: (2013-02-01)